History | Ocrelizumab for treating relapsing–remitting multiple sclerosis | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 230 KB)

Published:

25 July 2018

Final appraisal determination

Final appraisal determination
Final appraisal determination document (PDF 504 KB)

Published:

22 June 2018
Public committee slides (PDF 436 KB)

Published:

22 June 2018
Committee papers (PDF 4.43 MB)

Published:

22 June 2018

Draft guidance

Draft guidance
Appraisal consultation document (PDF 428 KB)

Published:

05 April 2018
Public committee slides (PDF 1.03 MB)

Published:

05 April 2018
Committee papers (PDF 22.75 MB)

Published:

05 April 2018

Invitation to participate

Final scope (PDF 109 KB)

Published:

03 October 2017
Final matrix (PDF 252 KB)

Published:

03 October 2017
Equality impact assessment (Scoping) (PDF 174 KB)

Published:

26 September 2017
NICE's response to comments on the draft scope and provisional matrix (PDF 490 KB)

Published:

03 October 2018

Draft scope documents

Draft scope (pre-referral) (PDF 131 KB)

Published:

31 January 2017
Provisional matrix (pre-referral) (PDF 37 KB)

Published:

31 January 2017